Roche

ESMO 2022 – Keytruda secures a renal cancer monopoly
EP Vantage
Thu, 09/8/22 - 12:03 am
Merck
Keytruda
renal cancer
Bristol Myers Squibb
Roche
ESMO
Roche pays $250 million to acquire Good Therapeutics and its preclinical cancer therapy
Stat
Wed, 09/7/22 - 10:45 am
Roche
M&A
Good Therapeutics
cancer
oncology
PhoreMost in drug target discovery collaboration with Roche
Pharma Times
Wed, 09/7/22 - 10:21 am
Roche
PhoreMost
drug development
Brace for an end-of-year boost to drug approvals
EP Vantage
Fri, 09/2/22 - 12:14 pm
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
Interchangeability without switching studies: FDA explains why a new Lucentis biosimilar may be a game-changer
Endpoints
Thu, 08/25/22 - 07:48 pm
FDA
interchangeability
biosimilars
Lucentis
Roche
Coherus Biosciences
Cimerli
China's Jemincare nabs $650M biobucks pact with Roche's Genentech for prostate cancer hopeful
Fierce Biotech
Thu, 08/18/22 - 12:36 pm
Roche
Genentech
China
Jemincare
biobucks
prostate cancer
Roche’s Polivy continues its regulatory dance, will head to FDA for a form of blood cancer
Endpoints
Tue, 08/16/22 - 11:17 am
Roche
Polivy
diffuse large B-cell lymphoma
FDA
Roche, Genentech sign license deal with Kiniksa for vixarelimab
Pharmaceutical Business Review
Thu, 08/4/22 - 10:54 am
Kiniksa Pharmaceuticals
Roche
Genentech
vixarelimab
monoclonal antibodies
Coherus wins FDA approval for second Lucentis biosimilar, its third drug
BioPharma Dive
Wed, 08/3/22 - 09:26 pm
Coherus Biosciences
biosimilars
Lucentis
Roche
Cimerli
It’s official: Roche is a Car-T player
EP Vantage
Wed, 08/3/22 - 10:42 am
Roche
CAR-T
oncology
Poseida Therapeutics
Racing Merck and Pfizer, Roche readies to file subcutaneous Tecentriq after posting phase 3 data
Fierce Pharma
Tue, 08/2/22 - 10:54 am
Roche
Pfizer
Merck
Tecentriq
clinical trials
cancer
checkpoint inhibitors
Sarepta shares buoyed by pledge to seek an early swift review for Duchenne gene therapy
Fierce Biotech
Fri, 07/29/22 - 10:20 am
Sarepta Therapeutics
SRP-9001
Duchenne Muscular Dystrophy
Roche
accelerated approvals
Look out, Regeneron. As the threat from Roche's Vabysmo grows, one team of analysts slashes its Eylea sales estimate
Fierce Pharma
Mon, 07/25/22 - 10:00 pm
Regeneron
Eylea
Roche
Vabysmo
Roche, Biogen temper Alzheimer’s expectations in Q2 calls. Will Lilly follow suit in August?
Fierce Biotech
Fri, 07/22/22 - 11:21 am
Alzheimer's disease
Roche
Biogen
Eli Lilly
lecanemab
gantenerumab
Aduhelm
Roche Sees More Growth Opportunities for Phesgo, Tecentriq; Still Optimistic on Tiragolumab
Precision Oncology News
Fri, 07/22/22 - 10:14 am
Roche
earnings
oncology
Phesgo
Tecentriq
Roche CEO Severin Schwan to step down after 14 years
Pharmaforum
Thu, 07/21/22 - 10:42 am
Roche
Pharma CEOs
Severin Schwan
Thomas Schinecker
Genentech rides up to 2nd target in Bicycle immuno-oncology collab
Fierce Biotech
Tue, 07/12/22 - 10:52 am
Genentech
Bicycle Therapeutics
Roche
immuno-oncology
Ionis hands off an antisense drug for kidney disease, giving all rights to Roche
Endpoints
Mon, 07/11/22 - 06:23 pm
Ionis Pharmaceuticals
Roche
IONIS-FB-LRx
clinical trials
immunoglobin A nephropathy
kidney disease
AstraZeneca, GSK and more weathered Q2's economic headwinds, but Roche's stock took a hit: analysts
Fierce Pharma
Wed, 07/6/22 - 11:41 pm
AstraZeneca
GSK
Roche
FDA to decide on Roche’s lymphoma drug Lunsumio before year-end
Pharmaforum
Wed, 07/6/22 - 10:49 am
Roche
Lunsumio
follicular lymphoma
T-cell engager
FDA
priority review

Pages